Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750291 | 1.00 | MEN1 (0.36) | MEN1CYP3A4CYP2D6KMT2ADRD2 | |
| SCHEMBL3706859 | 0.81 | MEN1 (0.38) | MEN1CYP3A4CYP2D6KMT2ADRD2 | |
| SCHEMBL3706863 | 0.81 | MEN1 (0.38) | MEN1CYP3A4CYP2D6KMT2ADRD2 | |
| SCHEMBL3741386 | 0.76 | ATM (0.32) | MEN1CYP3A4CYP2D6KMT2ADRD2 | |
| SCHEMBL3741380 | 0.76 | ATM (0.32) | MEN1CYP3A4CYP2D6KMT2ADRD2 | |
| SCHEMBL1950686 | 0.75 | MEN1 (0.43) | MEN1CYP3A4CYP2D6KMT2ADRD2 | |
| SCHEMBL3748797 | 0.74 | SLC6A4 (0.39) | DRD2DRD1 | |
| SCHEMBL3748794 | 0.74 | SLC6A4 (0.39) | DRD2DRD1 | |
| SCHEMBL3751168 | 0.71 | CYP2A6 (0.36) | MEN1CYP3A4CYP2D6KMT2ASMN1; SMN2 | |
| SCHEMBL3745883 | 0.70 | CNR2 (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | MEN1 2774/4885CYP3A4 3682/4885CYP2D6 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.